It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The rapid qualitative assessment of surface markers on cancer cells can allow for point-of-care prediction of patient response to various cancer drugs. Preclinical studies targeting cells with an antibody to “activated” matriptase conjugated to a potent toxin show promise as a selective treatment for a variety of solid tumors. In this paper, we implemented a novel technique for electrical detection of proteins on surfaces of cancer cells using multi-frequency microfluidic impedance cytometry. The biosensor, consists of two gold microelectrodes on a glass substrate embedded in a PDMS microfluidic channel, is used in conjugation with immuno-magnetic separation of cancer cells, and is capable of differentiating between bare magnetic beads, cancer cells and bead-cell aggregates based on their various impedance and frequency responses. We demonstrated proof-of-concept based on detection of “activated” matriptase proteins on the surface of cultured Mantle cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Rutgers University New Brunswick; Department of Electrical and Computer Engineering, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
2 Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
3 Georgetown University, School of Medicine, Washington, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)
4 Rutgers University New Brunswick; Department of Electrical and Computer Engineering, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)